Patents by Inventor Per-Göran Gillberg

Per-Göran Gillberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20220402885
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: July 18, 2022
    Publication date: December 22, 2022
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkami
  • CRYSTAL MODIFICATIONS OF ODEVIXIBAT
    Publication number: 20220281832
    Abstract: The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-?-[N—((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modifications 1 and 2 of odevixibat. The invention also relates to a process for the preparation of crystal modification 1 of odevixibat, to a pharmaceutical composition comprising crystal modification 1, and to the use of this crystal modification in the treatment of various conditions as described herein.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 8, 2022
    Inventors: Robert Lundqvist, Ingvar Ymen, Martin Bohlin, Eva Byröd, Per-Göran Gillberg, Anna-Maria Tivert, Rikard Bryland, Jessica Elversson, Nils Ove Gustafsson, Ann-Charlotte Dahlquist
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 11377429
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: July 5, 2022
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Crystal modifications of odevixibat
    Patent number: 11365182
    Abstract: The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-?-[N—((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modifications 1 and 2 of odevixibat. The invention also relates to a process for the preparation of crystal modification 1 of odevixibat, to a pharmaceutical composition comprising crystal modification 1, and to the use of this crystal modification in the treatment of various conditions as described herein.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: June 21, 2022
    Assignee: Albireo AB
    Inventors: Robert Lundqvist, Ingvar Ymen, Martin Bohlin, Eva Byröd, Per-Göran Gillberg, Anna-Maria Tivert, Rikard Bryland, Ann-Charlotte Dahlquist, Jessica Elversson, Nils Ove Gustafsson
  • BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20220162176
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: February 10, 2022
    Publication date: May 26, 2022
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Treating Progressive Familial Intrahepatic Cholestasis (PFIC)
    Publication number: 20220143043
    Abstract: Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.
    Type: Application
    Filed: December 10, 2021
    Publication date: May 12, 2022
    Inventors: Per-Göran GILLBERG, Jan MATTSSON, Pat HORN, Paresh SONI
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 11306064
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: April 19, 2022
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Jan Mattsson, Ingemar Starke, Santosh S. Kulkarni
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 11267794
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: March 8, 2022
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • IBAT inhibitors for the treatment of liver diseases
    Patent number: 11261212
    Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: March 1, 2022
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Hans Graffner, Ingemar Starke
  • BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20220041567
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 10, 2022
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20220041568
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (1). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Benzothiadiazepine compounds and their use as bile acid modulators
    Patent number: 11225466
    Abstract: The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: January 18, 2022
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20210387956
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 16, 2021
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 11180465
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: November 23, 2021
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES
    Publication number: 20210340175
    Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
    Type: Application
    Filed: March 19, 2021
    Publication date: November 4, 2021
    Inventors: Per-Göran Gillberg, Hans Graffner, Ingemar Starke
  • BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20210299141
    Abstract: The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: April 28, 2021
    Publication date: September 30, 2021
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 11111224
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: September 7, 2021
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • PHARMACEUTICAL FORMULATION OF ODEVIXIBAT
    Publication number: 20210236511
    Abstract: The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.
    Type: Application
    Filed: June 20, 2019
    Publication date: August 5, 2021
    Inventors: Eva Byröd, Per-Göran Gillberg, Anna-Maria Tivert, Rikard Bryland, Ann-Charlotte Dahlquist, Jessica Elversson, Nils Ove Gustafsson, Robert Lundqvist, Ingvar Ymen, Martin Bohlin
  • BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20210179572
    Abstract: The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: December 22, 2020
    Publication date: June 17, 2021
    Inventors: Per-Göran Gillberg, Jan Mattsson, Ingemar Starke, Santosh S. Kulkarni
  • PHARMACEUTICAL FORMULATION OF ODEVIXIBAT
    Publication number: 20210177767
    Abstract: The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.
    Type: Application
    Filed: December 7, 2020
    Publication date: June 17, 2021
    Inventors: Eva Byröd, Per-Göran Gillberg, Anna-Maria Tivert, Rikard Bryland, Ann-Charlotte Dahlquist, Jessica Elversson, Nils Ove Gustafsson, Robert Lundqvist, Ingvar Ymen, Martin Bohlin